ARCHIVES

ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay

This article is from The Cancer Letter archive.

Vol. 35 No. 28 | July 17, 2009

Download PDF Visit The Full Archive

Related Articles

Herceptin Reduces Recurrence In Early HER2+ Breast Cancer

September 30, 2005

NSABP Accrual Slow, But Auditing Called “Impressive”

January 20, 1995

Bush Limits Drug Company Efforts To Block Generics

October 25, 2002

Potti Claimed Rhodes Credential in Bio Submitted for DOD Funding

July 30, 2010

FDA Adopts Plan For Drug Approval After Phase 2; Chabner Unconvinced

November 4, 1988

Letter: No Intent To Link Flags With NSABP Inquiry, ORI’s Bivens Writes

March 10, 1995